Atorvastatin AND Aspirin

Phase 1Small molecule

FFox Chase Cancer Center

Atorvastatin AND Aspirin is one of 7 small molecule programs targeting Lynch syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lynch SyndromeActive, not recruiting

Lynch SyndromePhase 1

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Lynch Syndrome

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Phase 3

2 2

Opdivo

Bristol-Myers Squibb

Phase 2

1 3

Aleve

Alnylam Pharmaceuticals

Phase 2

1 4

PD-1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 5

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 1

1 6

Anktiva

SSWOG Cancer Research Network

Phase 2

1 7

Atorvastatin AND Aspirin

FFox Chase Cancer Center

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lynch syndrome1 trial

Atorvastatin ± Aspirin in Lynch Syndrome Syndrome

Completed·FFox Chase Cancer Center·Phase 1·NCT04379999·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Atorvastatin AND Aspirin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Atorvastatin AND Aspirin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Atorvastatin AND Aspirin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fox Chase Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: FFox Chase Cancer Center

Atorvastatin AND Aspirin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lynch syndrome1 trial

References

Drug Info

Quick Facts

Related News